



**INTERNATIONAL JOURNAL OF**

*Medical Research*

*And*

*Practice*

**VOL. 1      ISSUE 3**

**(OCTOBER-DECEMBER'2016)**

# Call for Papers

We are delighted to announce the new ***International Journal of Medical research and Practice*** is now open for submissions.

The ***International Journal of Medical research and Practice*** focuses on all aspects of medical science. It is a medical journal would be accepting articles from Anatomy, Physiology, Biochemistry, Pharmacology, Microbiology, Pathology, Forensic & State Medicine, ENT, Sleep disorder and management, Ophthalmology, Preventive Medicine and Public Health, General Medicine, General Surgery, Obstetrics & Gynecology, Pediatrics, Radiology, Radiotherapy, Respiratory Medicine, Dermatology, Psychiatry, Orthopedics & other super specialty medical branches. We also accept articles from Dental and Nursing sciences.

This is an open access journal which means that all content is freely available without any charges to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission from the publisher or the author.

We welcome articles from all medical specialties. We accept Review articles, Research/Original articles, Case Reports, Case series, Research letters & Letters to Editor in English language.

The journal offers a single, peer-reviewed, multi-disciplinary platform for doctors and scientists in academia, hospitals, research institutions and government agencies and industry related to medical science. The Editor-in-Chief of ***International Journal of Medical research and Practice*** is [Dr. Pratyay Pratim Datta](#), Dept. of Pharmacology, Gouri Devi Institute of Medical Sciences and Hospital. He is supported by an international and national Editorial Board of leading experts in the field of medical science.

Authors who prefer to publish their articles as open access in ***International Journal of Medical research and Practice*** are

entitled to a **reduced publication fees** mentioned below if they submit their manuscripts by 15 May 2016.

To view the journal's Aims & Scope and the Guide for Authors, and for information on how to submit your paper, please check below.

The editors of ***International Journal of Medical research and Practice*** are now considering papers for publication and welcome your submission.

### ***Why IJMRP:***

- ✓ Minimum publication fees
- ✓ Editorial board across all specialties including super-specialties disciplines
- ✓ Quick review process
- ✓ Copy editing and language editing will be done by journal authority for the first issue. So, you will have to submit only doc or docx file
- ✓ First author of best paper in a issue would get a certificate from journal authority and his/ her next article in this journal would be 100% free

### Publication Fee:

For Indian Authors			
Type of Article	Actual Price (INR)	Discounted Price for PG Student (INR)	Discounted Price for Faculty and Practitioner (INR)
Original Article	4000	1000	1500
Review Article	4000	1000	1500
Case Report	2000	500	1000
Short Communication	2000	500	1000
Letter to the Editor	2000	500	1000
Editorial	2000	500	1000

## For International Authors

Type of Article	Actual Price (USD)	Discounted Price for PG Student(USD)	Discounted Price for Faculty and Practitioner (USD)
Original Article	<b>\$150</b>	<b>\$30</b>	<b>\$50</b>
Review Article	<b>\$150</b>	<b>\$30</b>	<b>\$50</b>
Case Report	<b>\$100</b>	<b>\$20</b>	<b>\$40</b>
Short Communication	<b>\$100</b>	<b>\$20</b>	<b>\$40</b>
Letter to the Editor	<b>\$100</b>	<b>\$20</b>	<b>\$40</b>
Editorial	<b>\$100</b>	<b>\$20</b>	<b>\$40</b>

# **International Journal of Medical Research and Practice**

**Volume: 1 Issue: 3  
(October-December, 2016)**

## **Editorial:**

### **1. Bring humanity in medicine**

*Ranabir Pal*

*IntJMRP 2016; 1(3): 1-3*

## **Review article:**

### **A comparative review of the current management guidelines in type 2 diabetes mellitus**

*Subham Das, Abheek Das*

*IntJMRP 2016; 1(3): 4-11*

## **Letter to the Editor:**

### **Oral anti-diabetics: What after metformin**

*Sayak Roy*

*IntJMRP 2016; 1(3): 12-12*

## **Case report:**

### **Bilateral linguofacial trunk in a cadaver**

*Arpan Haldar*

*IntJMRP 2016; 1(3): 13-15*



## Bring humanity in medicine

Ranabir Pal, Shivani Rao, Yarasani Pradeep

Professor and Chair, Assistant Professor, Department of Community Medicine, Andaman & Nicobar Islands Institute of Medical Sciences (ANIIMS), Port Blair 744104, India

Submission: 00-00-2016

Revision: 00-00-2016

Publication: 00-00-2016

The social and spiritual determinants of health are reflected in accessing health care as a barrier to universal health coverage as embedded in the primary health care imbibed by Sustainable Development Goals (SDG) – to the last man at the end of road in search of universal health coverage. The present health care trainings in the new millennium shows paucity of efforts to sensitize learners to the patient centered comprehensive clinical care across all age groups and organ systems. The capacity building in 'Medicine' demands expertise in catering to patient care needs in both acute and chronic illnesses from emergencies to palliative cares of all spectrums. Further, the community demands state-of-art health care supported by outpatients and inpatients facilities at all levels to provide skills in comprehensive health care at individual patient at the community levels also. Yet at the grassroots a primary care physician is expected to know everything on earth from inventory control to licit and illicit substance use.<sup>1-3</sup>

We have to shed our inhibitions to educate our inheritor descendants that medicine is a para-science where millions of risk factors and outcomes are also controlled by millions of confounders from the social systems; many of them are unknown and embedded in the age old human civilizations. We have to internalize that the social factors have impact from initiation to closing stages of any disease process in the natural history of disease like a 'full length feature film'. In fact the care-seekers present them with a 'snapshot' to the health care providers who have to visualize the retrospect and prospect of the disease with his lifelong accumulation of knowledge, attitude, and skills.

Some instances will help realize in simple terms. Even a school going kid in the new millennium knows that *Human immunodeficiency virus (HIV)* causes a mortal illness and condom use can prevent this. But they are rarely educated about the social and spiritual factors behind the global disaster of HIV infection. If a couple is faithful to each other in their life, then even if they never use condom, exceptionally can contract HIV infection by 'true' extra-sexual routes, though they may have 'n' number of children out of their 'unprotected' sexual behavior increasing maternal and childhood ill-health due to other reasons. We can now count on the tragedy of the pandemic as the outcome of millions of spells of unhappiness within the marriage institutions and loss of taboo on premarital as well as extramarital sex; those

are traditionally by all dimensions unlikely to be faithful. HIV has opened a Pandora's Box that 'animal character of polygamy' is prevalent phenomenon that has helped survive 'prostitution' as the primitive as well as oldest profession of human civilization.

Oropharyngeal carcinoma and intra-abdominal lymphoma are increasingly being reported with their association with *Human immunodeficiency virus (HPV)* infection that is classically been incriminated for evolution of cervical carcinoma. To trace the journey of the HPV to the alimentary tract from the female genitalia, social scientists have postulated epidemiological link of all forms of mysterious as well as uncanny carnal activities involving oral end of body. Of course, later on microbiological substantiation has corroborated the astounding evidence. So the magnificent volume of sanction of oro-genital sex within 'normal' human behavior is being slowly delineated as a less known truth to the health care providers that sexually transmitted infections is swelling in numbers.

Similar natural history of illness will be worthy of mentioning for *Helicobacter pylori* in the causation of changes in gastric mucosa leading to the ulcerative processes and malignancies. Whether unhygienic conditions help entry and proliferation of this deadly organism through fecal-oral routes in the early life to be manifested in later life has been a bone of contention for the scientists. Millennium Development Goal targeted to half Indian population without access to drinking water and sanitation by 2015. Even if we achieve this mark, 244 million people in rural India and 90 million in urban India will still not have access to safe, sustainable water supply.<sup>4</sup>

While policy makers keep mum on the issue of failure of coverage of family planning or immunization even after five decades of implementation at the expense of tax of common men. Further at the end of seventh decade of independence the policy makers promulgated that optimal health can only be ensured by uprooting socio-economic causation of diseases by providing safe water and sanitation as the basic right of citizens.<sup>5</sup>

Although these diseases were always been present in historical reports too, not necessarily new illnesses due to social behavior changes, yet research works have been able to explain the natural history of many interlinked

pathogenesis. Apart from the above scenarios, there has been re-incarnation of 'Germ theory' in the womb of biotechnological revolution in the field of laboratory medicine wherein a good number of malignant and non-malignant diseases have been traced back to microbial infections. In this approach if we go on risk factor finding efforts, one day we may reach to a conclusion that the barrier between communicable and non-communicable diseases is nothing but a traditionally percolated artificial watershed.<sup>6</sup>

There is no doubt about vulnerability of tobacco as all round risk of causation of diseases – tobacco in any form is injurious to health. So our world is moving in the right direction to stop use of all forms of tobacco, hand in gloves with the global movement. But what's about alcohol? If we ever get time to think of social devastation of alcohol we may have been perplexed. We have to honestly find answer to the silent uncomfortable questions. 'How many families have been ruined by the alcohol addiction of the bread earner?', 'What is the true magnitude of morbidity and mortality of road traffic injury due to alcohol', 'How many lives have been damaged by domestic and interpersonal violence by the inebriated millions?' so on and so forth. Till date we have heard of only a handful of country banning consumption of all forms of liquor including few states of India; even nine countries repealed banning after some years.<sup>7</sup>

History has shown that correct opinion is always a minority at the beginning. What has been personal opinion or group view or even about freedom of choice or ethics of yesterday, later on allows or ban? Individual holds may not be ethical to enforce in society, yet community opinions too play an important role. Yet, citizens do not hesitate to invest in share and debentures of tobacco and liquor companies with an idea of gaining profit by their ever increasing sales (consumption) curve. So we have to think hundred times of the limited utility as well as right to campaign against tobacco- and alcohol-related health hazards.

Let us move onto other flip side of clinical medicine. We generally promote clinical suggested breast examination for early non-invasive indication of Carcinoma of Breast (Ca-Breast). But onco-pathologists feel that this method does not help in early diagnosis of Ca-Breast as minimum 2 cm of dimension is needed for manual palpation not only by laymen but also by the health care providers. Instead mammography with high sensitivity and specificity should have to be promoted in countries for early diagnosis of breast cancers in resource poor settings also (just like cervical cytology could have been able to breakthrough in cervical cancer).<sup>8</sup>

Health care providers need to be updated on the rational use of drugs and protocol based management of serious infections that are supported by current research. Yet the scientists of today have proposed a newer idea that the concept of 'Expiry of drug' should have been revised in the light of recent advancement of good manufacturing practices as no recent reports in the literature support that ingestion, injection, or topical application of current drug formulations used beyond their expiration date have resulted in major

adverse drug reactions (ADRs). Even after expiry of date any drug if kept in the original sealed container will retain 90 percent efficacy for another 5 years whether it is oral, topical, parenteral does not matter. Some literature also reported 88 percent stability for more than 5 years after original expiration date when stored in their original sealed container. All these updates have to be shared with the future physicians from day one and facilitators of learning should be courteous to accept shortcomings of updating, if any openly.<sup>9-11</sup>

We have to a soul search that, why after the discovery of hundreds of 'curative' drugs for hundreds of older morbidities, they are still not manageable by curative approaches only. The most brilliant example is resurfacing of tuberculosis in the era of HIV pandemic. We have to accept the bitter pill that malaria cannot be controlled by anti-malarial drugs alone as the disease has multiple social causations like all other vector-borne diseases. As the health care provider if we think that the limits of our responsibility ends with the correct diagnosis and prescription to the best of knowledge, ability and skill, then we are behaving like the ostrich to hide in the sand to keep unsighted for incoming adversaries. In the hundreds of medical schools across our country thousands of managements of health-related problems are taught along with pathogenesis. Yet rarely 'Salutogenesis' is communicated to a good number of learners. The concept of salutogenesis have been introduced in late seventies of last millennium by Aaron Antonovsky converging on influences of socio-demographic-economic-political factors in different permutations and combinations that keeps wellbeing of people in health. Conceptually salutogenesis has hailed the perpetually overlooked ideation of 'Health promotion' that leads to the outcomes of healthiness.<sup>12,13</sup>

Life is a learning process, no matter where we are, what titles or positions we have or had under our belts, or how old we are, there are always things out there for us to experience and learn. Because we can never finish learning everything that life has to offer. But one of the few things we have learned so far is to be true to oneself – to be honest and sincere in the things that we do, to be happy doing it and if sharing, share genuinely. So if we can honestly justify our actions to ourselves, then no one else's opinions matter. Principles and ethics of life need to be adhered to. We cannot stop people from their actions but theirs is not for us to judge. We just need to take care of our own actions and be true to ourselves and be happy doing it. This is reminiscent of Ariel's dictum: "Bricks and mortar do not make institutions but those who work them". No matter how beautiful the buildings, and no matter how sophisticated the equipment in health facilities, it is the knowledge, skills, attitude, and behavior of the health workers that prevent and reduce morbidity and mortality.<sup>14</sup>

## REFERENCES

1. National Health Policy 2015 Draft. Ministry of Health & Family Welfare December 2014, p. 11. [online] [retrieved on 06.02.2016]. Available from: <http://www.mohfw.nic.in/WriteReadData/l892s/35367973441419937754.pdf>.
2. Pal R, Ghosh BN. A study on the existing system of inventory control and material management in a Central Medical Store. Indian J Community Med 1991;XVI(3):130-135 [PubMed].

3. Tsering D, Pal R, Dasgupta A. Licit and illicit substance use by high school students in Eastern India: prevalence and associated risk factors. *J Neurosci Rural Pract* 2010;1:74–79 [PubMed].
4. 2015: 334 million Indians will still lack access to safe water supply. [online] [cited 20.05.2015]. Retrieved from: <http://infochangeindia.org/agenda/the-politics-of-water/2015-334-million-indians-will-still-lack-access-to-safe-water-supply.html>.
5. Sanitation as a Human Right. [online] [cited 20.05.2015]. Retrieved from: <http://www.unric.org/en/sanitation/27281-sanitation-as-a-human-right>.
6. Marrazzo JM, Holmes KK. Major STD syndromes and sexually transmitted microbial etiologies. In: *Sexually Transmitted Infections: Overview and Clinical Approach*. Harrison's Principles of Internal Medicine. 18th ed., Vol. 1. The McGraw-Hill Companies Inc., 2012. p. 1097.
7. List of countries with alcohol prohibition. [online] [cited 20.05.2015]. Retrieved from: [http://en.wikipedia.org/wiki/List\\_of\\_countries\\_with\\_alcohol\\_prohibition](http://en.wikipedia.org/wiki/List_of_countries_with_alcohol_prohibition).
8. Mayer M, Batur P. Breast Disorders and Breast Screening [online] [cited 20.05.2015]. Retrieved from: <http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/womens-health/breast-disorders-and-cancer-screening/Default.htm>.
9. Tsering DC, Chanchal L, Pal R, Kar S. Bacteriological profile of septicemia in neonates and infants with the associated risk factors in Sikkim. *J Global Infect Dis* 2011;4(1):43–46 [PubMed].
10. Pal R. Rational use of drugs. *J Neurosci Rural Pract* 2011;2(2):123–124 [PubMed].
11. Pierson JC. Let's put an expiration date on the current approach to drug expiration dates. *J Am Acad Dermatol* 2014;71(1):193–194.
12. Antonovsky A. The salutogenic model as a theory to guide health promotion. *Health Promotion Int* 1996;11(1):11–18.
13. Lindström B. Salutogenesis – an introduction [online] [cited 20.05.2015]. Retrieved from: <http://www.ndphs.org//documents/2502/SALUTOGEN%20ESIS%20and%20NCDs.pdf>.
14. Ana J. why it is important to meet the Health information needs of Health workers in developing Countries [online] [cited 13 May 2014]. Available from: <http://www.hifa2015.org/wp-content/uploads/Joseph-Ana-HIFA2015-Conference-2011.pdf>.

#### Address for Correspondence:

Ranabir Pal,  
MD, PhD, MBBS (Honors), DCH, MBA, CMCL-FAIMER FELLOW,  
M.A.M.S, M.N.A.Sc.  
Professor and Chair, Department of Community Medicine,  
Andaman & Nicobar Islands Institute of Medical Sciences  
(ANIIMS), Port Blair 744104, India  
**Mobile:** +91 94 33 247676; **Tel.:** +91 80039 96867, +91 94332 47676  
**E-mail:** ranabirmon@yahoo.co.in, ranabirmon@gmail.com

**How to cite this article:** Pal R, Rao S, Pradeep Y. Bring humanity in medicine. *IntJMRP* 2016;1(2):pp–pp.

**Source of Support:** None declared. **Conflict of Interest:** None.



## A comparative review of the current management guidelines in type 2 diabetes mellitus

Subham Das, Abheek Das

Submission: 00-00-2016

Revision: 00-00-2016

Publication: 00-00-2016

Address for Correspondence:

### ABSTRACT

**Background:** Diabetes mellitus is a modern day epidemic, majority of the cases belonging to type 2. In spite of having many different guidelines given by many professional bodies as to the screening, diagnosis, and management of diabetes and related complications, physicians all over the globe are yet to reach a clear consensus regarding the same. **Objective:** With this background knowledge, the objective of the present review is to find out the areas of common consensus among various popular guidelines regarding type 2 diabetes mellitus, and more importantly, the aspects of various guidelines where there is significant disagreement among the guidelines. **Method:** Various popular diabetes-related guidelines given by WHO, ADA-EASD position statement, AACE, etc. were reviewed and the various aspects of their guidelines, especially the area where the guidelines are in disagreement among them were noted. **Results and conclusion:** The popular guidelines on type 2 diabetes mellitus were critically reviewed and the principal points of each of the guidelines are explained along with the areas of divergence among all the guidelines.

**Key words:** Type 2 diabetes mellitus, Guidelines of diabetes, ADA-EASD position statement, AACE

### GLOBAL BURDEN OF DIABETES

Briefly, 415 million (age group in between 20 and 79 years) people are living with diabetes worldwide with prevalence of 8.8%. In total, 77% of people with diabetes live in low and middle income countries. According to International Diabetes Federation by 2040, the expected number of population with disease burden will be 642 million. In India, in 2015 total number of people with diabetes (age between 20 and 79 years) was 69.2 million and expected to increase to 123.5 million by 2040. In South East Asia, the number of people with diabetes mellitus is 78 million and death because of diabetes is 1.2 million.<sup>1</sup> Evidence based clinical guidelines are often regarded as the best tools for the management of any chronic disease like type 2 diabetes mellitus and thus provide a benchmark to achieve optimal patient outcome. There are various recommendations currently followed in different parts of the world issued by various international and national bodies or professional organizations as to management of type 2 diabetes mellitus and/or its complications. These include guidelines from the American Diabetes Association (ADA), the European Association for the Study of Diabetes (EASD), the World Health Organisation (WHO), the American Association of Clinical endocrinologists (AACE), International Diabetes Federation (IDF), etc. Others like

Indian Council of Medical Research (ICMR), the Indian Health Service (IHS) have also issued management guidelines from time to time. Of them, the AACE document is a series of algorithms with very minimal text which mainly deals with all facets of type 2 diabetes, i.e., hyperglycemia, obesity, pre-diabetes, hypertension, and dyslipidemia. Whereas the ADA/ the present study focuses mainly on comparing various type 2 diabetes management protocols and guidelines currently in practice by diabetologists in a diverse geographical areas. Undoubtedly local incidence and disease patterns influence the respective guidelines, still considering the fact that type 2 diabetes mellitus is now considered as a modern day epidemic, this article reviews the similarities and deviations amongst various existent guidelines.

### CURRENT TRENDS IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS

#### AACE (American Association of Clinical Endocrinologist) principles of management of type 2 diabetes mellitus<sup>2</sup>

(1) Lifestyle optimization and education are essential for all patients with diabetes. Lifestyle modification designed for weight loss, including medical and surgical interventions

approved for the treatment of obesity, should be considered as primary approaches for therapeutic benefits in overweight and obese patients with diabetes, and for prevention of diabetes, and for prevention of diabetes in high risk patients with prediabetes. The treatment of overweight/obesity in patients with type 2 diabetes and prediabetes should proceed according to the Obesity Treatment Algorithm. Effective interventions for weight loss involve a multidisciplinary team. The need for medical therapy for weight loss or glycemic control should not be considered as a failure of lifestyle management, but as an adjunct to it.

(2) The HbA1c target must be individualized, based on numerous factors, such as age, comorbid conditions, duration of diabetes, risk of hypoglycemia, patient motivation, adherence, life expectancy, etc. An HbA1c of 6.5% or less is still considered optimal if it can be achieved in a safe and affordable manner, but higher targets may be appropriate and may change in a given individual over time.

(3) Minimizing risk of hypoglycemia is a priority. It is a matter of safety, adherence, and cost.

(4) Glycemic control targets include fasting and postprandial glucose as determined by self-blood glucose monitoring.

(5) Minimizing risk of weight gain is a priority and is a matter of safety, adherence, and cost.

(6) The choice of therapies must be individualized based on attributes of the patient (as above) and the medications themselves. Attributes of medications that affect their choice include risk of inducing hypoglycemia, risk of weight gain, and ease of use, cost and safety impact of kidney, heart, or liver disease. This algorithm also stratifies choice of therapies based on initial HbA1c.

(7) The algorithm provides guidance to what therapies to initiate and add, but respects individual circumstances that would make different choices.

(8) Therapies with complementary mechanisms of action must typically be used in combinations for optimum glycemic control.

(9) Effectiveness of therapy must be evaluated frequently until stable (e.g., every 3 months) using multiple criteria including HbA1c, SMBG (self-monitoring of blood glucose) records including both fasting and postprandial data, documented and suspected hypoglycemia, and monitoring for other potential adverse events (weight gain, fluid retention, hepatic, renal, or cardiac disease) and monitoring of comorbidities, relevant laboratory data, concomitant drug administration, diabetic complications, and psychosocial factors affecting patient care.

(10) Safety and efficacy should be given higher priorities than initial acquisition cost of medications per se since cost of medication is only a small part of the total cost of a medication, consideration should be given to monitoring requirements, risk of hypoglycemia, weight gain, etc.

(11) The algorithm should be as simple as possible to gain physician acceptance and improve its utility and usability in clinical practice.

(12) The algorithm should serve to help educate the clinician as well as to guide therapy at the point of care.

(13) The algorithm should conform as nearly as possible to a consensus for current standard of practice of care by expert endocrinologists who specialize in the management of patients with type 2 diabetes and have the broadest experience in outpatient clinical practice.

(14) The algorithm should be as specific as possible, and provide guidance to the physician with prioritization and a rationale for selection of any particular regimen.

(15) Rapid acting insulin analogues are superior to NPH insulin because they provide a fairly flat response for approximately 24 h and provide better reproducibility and consistency both between subjects and within subjects with a corresponding reduction in the risk of hypoglycemia.

## **Standards of Medical Care in Diabetes – 2016 (American Diabetic Association) and European Association for the Study of Diabetes (EASD) Position Statement**

### **1) Strategies for Improving Care**

- a) A patient centered communication style that incorporates patient preferences, assesses literacy and numeracy, and addresses cultural barriers to care should be used.
- b) Treatment decisions should be timely and founded on evidence based guidelines that are tailored to individual patient preferences, prognosis, and comorbidities.
- c) Care should be aligned with components of the Chronic Care Model (CCM) to ensure productive interactions between a prepared proactive practice team and an informed activated patient.
- d) When feasible, care systems should support team-based care, community involvement, patient registries, and decision support tools to meet patient needs.
- e) People with diabetes should receive medical care from a collaborative, integrated team with expertise in diabetes. This team may include physicians, nurse practitioners, physicians' assistants, nurses, dietitians, pharmacists, and mental health professionals.

### **2) Diabetes Management**

#### **Glycemic recommendations for non-pregnant adults with diabetes**

- (i) HbA1c < 7.0 %

Pre-prandial capillary plasma glucose 80–130 mg/dl.  
Postprandial capillary plasma glucose < 180 mg/dl.

- a) Less stringent goals (such as < 8%) may be appropriate for patients with a history of severe hypoglycemia, limited life expectancy, advanced microvascular, or macrovascular complications, extensive comorbid conditions, or long standing diabetes in whom the general goal is difficult to attain despite diabetes self-management education, appropriate self-management education, appropriate glucose monitoring, and effective doses of multiple glucose lowering agent including insulin.

- b)** Providers might reasonably suggest more stringent HbA1C goals (such as < 6.5%) for selected individual patients if this can be achieved without significant hypoglycemia or other adverse effect of treatment. Appropriate patients might include those with short duration of diabetes, type 2 diabetes treated with lifestyle or metformin only, long life expectancy, or no significant cardiovascular disease.
- c) Lifestyle modification**
1. Diabetes self-management education and self-management support.
  2. Medical Nutrition Therapy – Individualized medical nutrition therapy. Meal planning from a registered dietitian. Comprehensive group diabetes education programs including nutrition therapy or individualized education sessions have reported HbA1C decreases of 0.3–1% for type 1 diabetes<sup>3–7</sup> and 0.5–2% for type 2 diabetes.<sup>8–15</sup>
- (ii) Carbohydrate management**  
A simple diabetes meal planning approach such as portion control or healthful food choices may be better suited for individuals.<sup>16–19</sup> Carbohydrate intakes from vegetables, fruits, whole grains, legumes, and dairy products should be advised over intake from other carbohydrate sources, especially those that contain added fats, sugars, or sodium. Individuals at high risk for type 2 diabetes should consume foods containing whole grains.
- (iii) Protein management**  
Mediterranean style eating pattern, rich in monounsaturated fatty acids is appropriate for type 2 diabetes mellitus.
- (iv) Dietary fat management** Increased consumption of foods containing long chain omega-3 fatty acids, such as fatty fish, and omega-3-linolenic acid (ALA) is recommended.  
The consumption of fish (particularly fatty fish) at least two times per week is recommended.
- (v) Physical activity**
- a) Children with diabetes or pre-diabetes should be encouraged to engage in at least 60 min of physical activity each day.
  - b) Adults with diabetes should be advised to perform at least 150 min/week of moderate intensity aerobic physical activity (50–70% of maximum heart rate), spread over at least 3 days/week with no more than 2 consecutive days without exercise.
  - c) Evidence supports that all individuals, including those with diabetes, should be encouraged to reduce sedentary time, particularly by breaking up extended amounts of time (> 90 min) spent sitting.
  - d) In the absence of contraindications, adults with type 2 diabetes should be encouraged to perform resistance training at least twice per week.
  - e) High risk patients should be encouraged to start with short periods of low intensity exercise and slowly increase the intensity and duration.
  - f) In individuals taking insulin or insulin secretagogues, physical activity can cause hypoglycemia if medication dose or carbohydrate consumption is not altered. For individuals on these therapies, added carbohydrate should be ingested if pre-exercise glucose levels are < 100 mg/dl.
- (vi) Smoking cessation**
- a) Patients should not smoke or use tobacco products.
  - b) Smoking cessation counselling and other forms of treatment as a routine component of diabetes care.
- (vi) Psychosocial assessment and care**
- a) Stepwise collaborative care approach for the management of depression.
  - b) Older adults (≥ 65 years) with diabetes should be considered a high priority population for depression screening and treatment.
  - c) Screen for psychosocial problems such as depression, diabetes-related distress, anxiety, eating disorders, and cognitive impairment.
  - d) Include assessment of the patient's psychological and social situation as an ongoing part of the medical management of diabetes.
- (vii) Immunization**
- a) Routine vaccination for children and adults with diabetes as for the general population.
  - b) Annually provide an influenza vaccine to all patients with diabetes ≥ 6 months of age.
  - c) Administer pneumococcal polysaccharide vaccine 23 (PPSV23) to all patients with diabetes ≥ 2 years of age.
  - d) Administer hepatitis B vaccination to unvaccinated adults with diabetes who are aged 19–59 years.
  - e) Consider administering hepatitis B vaccination to unvaccinated adults with diabetes who are aged ≥ 60 years.

### Pharmacological Therapy for Type 2 Diabetes

- a) Metformin if not contraindicated and if tolerated, is the preferred initial pharmacological agent for type 2 diabetes.
- b) If noninsulin monotherapy at maximum tolerated dose does not achieve or maintain the HbA1C target over 3 months, add a second oral agent, a GLP-1 receptor agonist, or basal insulin.
- c) Due to the progressive nature of type 2 diabetes, insulin therapy is eventually indicated for many patients with type 2 diabetes.
- d) In patients with newly diagnosed type 2 diabetes and markedly symptomatic and/or elevated blood glucose levels or HbA1C, consider initiating insulin therapy.
- e) A patient-centered approach should be used to guide choice of pharmacological agents. Considerations include efficacy, cost, potential side effects, weight, comorbidities, hypoglycemia risk, and patient preferences.

- f) Most patients should begin with lifestyle changes (life style counselling, weight loss education, exercise, etc.). When lifestyle efforts alone have not achieved or maintained glycemic goals, metformin monotherapy should be added at, or soon after diagnosis unless there are contraindications or intolerance.
- g) Metformin has a long standing evidence base for efficacy and safety, is inexpensive and may reduce risk of cardiovascular events.<sup>20</sup>
- h) In patients with metformin intolerance or contraindications, consider an initial drug from other classes like sulfonylurea or thiazolidinedione or DPP-4 inhibitor or GLP1 receptor agonist or basal insulin.
- i) If the HbA1c target is not achieved after approximately 3 months, consider a combination of metformin and one of the six treatment options: sulfonylurea, thiazolidinedione, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, basal insulin.
- j) Drug choice is based on patient preferences as well as various patient, disease, and drug characteristics, with the goal of reducing blood glucose levels while minimizing side effects, especially hypoglycemia.
- k) Rapid acting secretagogues (meglitinides) may be used instead of sulfonylureas in patients with irregular meal schedules or who develop late postprandial hypoglycemia on a sulfonylurea.
- l) For all patients, consider initiating therapy with a dual combination when HbA1c is  $\geq 9\%$  to more expeditiously achieve target HbA1c level.
- m) Insulin has the advantage of being effective where other agents may not be and should be considered as part of any combination regimen when hyperglycemia is severe, especially if symptoms are present or any catabolic features (weight loss, ketosis) are in evidence.
- n) Consider initiating combination insulin injectable therapy when blood glucose is  $\geq 300\text{--}350$  mg/dl and/or HbA1c is  $\geq 10\text{--}12\%$ .

### Insulin Therapy

- a) Basal insulin alone is the most convenient initial insulin regimen, beginning at 10 IU or 0.1–0.2 U/kg, depending on the degree of hyperglycemia.
- b) Basal insulin is usually prescribed in conjunction with metformin and possibly one additional noninsulin agent.
- c) If basal insulin has been titrated to an acceptable fasting blood glucose level, but HbA1c remains above target, consider advancing to injectable therapy to cover postprandial glucose excursions.

### Bariatric Surgery

- 1) Bariatric surgery may be considered for adults with Body Mass Index (BMI)  $> 35$  kg/m<sup>2</sup> and type 2 diabetes, especially if diabetes or associated comorbidities are difficult to control with lifestyle and pharmacological therapy.
- 2) Patients with type 2 diabetes who have undergone bariatric surgery need lifelong lifestyle support and medical monitoring.

## Cardiovascular Disease Risk Management

### A) Hypertension and blood pressure control

Blood pressure should be measured at every routine visit. Patients found to have elevated blood pressure confirmed on a separate day.

#### Goals

- a) People with diabetes and hypertension should be treated to a systolic blood pressure (SBP) goal of  $< 140$  mm of Hg.
- b) Individuals with diabetes should be treated to a diastolic blood pressure (DBP)  $< 90$  mm of Hg.
- c) Lower diastolic targets, such as  $< 80$  mm of Hg, may be appropriate for certain individuals, such as younger patients, if they can be achieved without undue treatment burden.
- d) Lower systolic targets, such as  $< 130$  mm of Hg, may be appropriate for certain individuals, such as younger patients, if they can be achieved without undue treatment burden.

### B) Dyslipidemia management

- a) Lifestyle modification focusing on the reduction of saturated fat, trans fat, and cholesterol intake, increase of omega-3-fatty acids, viscous fiber, and plant sterols/stools; and increased physical activity should be recommended to improve the lipid profile in patients with diabetes.
- b) Intensify lifestyle therapy and optimize glycemic control for patients with elevated triglyceride levels ( $\geq 150$  mg/dl) and or low HDL cholesterol ( $< 40$  mg/dl for men,  $< 50$  mg/dl for women).
- c) For patients with fasting triglyceride levels  $\geq 500$  mg/dl evaluate for secondary causes and consider medical therapy to reduce risk of pancreatitis.
- d) For patients of all ages with diabetes and overt cardiovascular disease (CVD) high intensity statin therapy should be added to lifestyle therapy.
- e) For patients with diabetes aged  $< 40$  years with additional CVD risk factors, consider using moderate or high intensity statin and lifestyle therapy.
- f) For all patients with diabetes aged 40–75 years or above with or without additional CVD risk factors, consider using high or moderate intensity statin and lifestyle therapy.
- g) Use aspirin therapy (75–162 mg/day) as a secondary prevention strategy in those with diabetes and a history of CVD.
- h) Consider aspirin therapy (75–162 mg/day) as a primary prevention strategy in those with type 1 or type 2 diabetes at increased cardiovascular risk (10-year risk  $> 10\%$ ). This includes most men aged  $> 50$  years or women aged  $> 60$  years who have at least one additional major risk factor (family history of CVD, hypertension, smoking, dyslipidemia or albuminuria).

### C) Coronary heart disease

- a) In patients with known CVD, use aspirin and statin therapy if not contraindicated and consider ACE inhibitor therapy to reduce the risk of cardiovascular events.



- b) In patients with MI,  $\beta$  blockers should be continued at least 2 years after the event.
- c) In patients with symptomatic heart failure, thiazolidinedione treatment should not be used.
- d) In patients with stable CHF, metformin may be used if renal function is normal but should be avoided in unstable or hospitalized patients with CHF.

#### Diabetic nephropathy

- a) Either an ACE inhibitor or ARB is suggested for the treatment of the non-pregnant patient with modestly elevated urinary albumin excretion (30–299 mg/day) and is recommended for those with urinary albumin excretion > 300 mg/day.
- b) An ACE inhibitor or ARB is not recommended for the primary prevention of diabetic kidney disease in patients with diabetes who have normal blood pressure and normal UACR (< 30 mg/g).

#### Diabetic retinopathy

- a) Patients with type 2 diabetes should have an initial dilated and comprehensive eye examination by an ophthalmologist or optometrist shortly after the diagnosis of diabetes.
- b) Optimize glycemic control and blood pressure control.

#### Diabetic neuropathy

- a) All patients should be screened for diabetic peripheral neuropathy (DPN) starting at diagnosis of type 2 diabetes and at least annually thereafter using simple clinical tests like 10 g monofilament.
- b) Tight glycemic control to slow down progression of diabetic neuropathy.
- c) Drugs like pregabalin, duloxetine, tapentadol, venlafaxine, amitriptyline, gabapentin, valproate, and other opioids like morphine may be effective.

### International Diabetes Federation Global Guidelines for Type 2 Diabetes Mellitus

Healthcare provided by International Diabetes Federation (IDF) has been divided into 3 types.

1. *Recommended care* – Cost-effective evidence-based health care.
2. *Limited care* – Healthcare for limited resources system.
3. *Comprehensive care* – Most up to date technology-based healthcare but some of the technologies are weak evidence based.

#### Diagnosis for Diabetes

Diagnosed as any one of the following criteria of WHO-FBG > 126 mg/dl or 75 mg OGTT test FBG > 126 mg/dl and or 2 h plasma glucose > 200 mg/dl.

Random blood glucose > 200 mg/dl with management of type 2 DM

#### Management of Type 2 DM

- A. Education
  - Patient-centered structured self-management education.

Appropriately trained multidisciplinary team if possible include family member in that team.

Education should be accessible to all population including culture, ethnicity, and psychosocial issue.

- B) Psychological care
  - Refer to a mental healthcare professional if severe coping problem, major depression, anxiety disorder, personality disorder, cognitive decline occurs.
- C) Lifestyle modification
  - a) Physical activity 30–40 min/day for 3–5 days per week or an accumulation of 150 min per week of moderate intensity exercise.
  - b) Reduce food which has high energy, added sugar, and alcohol.
  - c) Advice on food for prevention of management of hypoglycemia.
  - d) Nutritional counselling from professional nutritionist.

#### Glucose control levels

HbA1c < 7%

Primeval capillary plasma glucose < 115 mg/ dl

Postmeal capillary plasma glucose < 160 mg/ dl

#### Clinical monitoring

- a) Measure HbA1c at every 2–6 month interval.
- b) If HbA1c not available measure fructose amine or blood glucose.
- c) HbA1c should be measured by high-performance liquid chromatography or mass spectrometry.

#### Self-monitoring of blood glucose

- a) Self-monitoring of blood glucose should be done by making the patient knowledgeable on diabetes.
- b) Patient has to make willing and cooperative on self-monitoring.
- c) Both the healthcare provider and receiver should agree on self-monitoring of blood glucose.

#### Glucose control therapy

- A) First line of therapy
  - Metformin should be the first line of drug until and unless any other contraindications or renal impairment occurs.
  - Titrate the dose of metformin to counter gastrointestinal intolerance.
  - Monitor renal function and use metformin with caution if eGFR (estimated glomerular filtration rate) < 45 ml/min/1.73 m<sup>2</sup>.
  - Sulfonylurea can be added if high blood glucose level in some population and also alpha glucosidase inhibitor can be added.
  - In some conditions dual therapy can be started if monotherapy cannot maintain target blood glucose level.
- B) Second line of therapy
  - Sulfonylurea should be added as 2nd line therapy.
  - Other options may be metformin if not added as first line of therapy.
  - Alpha glucosidase inhibitor or DPP4 inhibitor or thiazolidinedione can be added.



- C) Third line of therapy  
Add oral antidiabetic agent or start insulin.  
If starting with insulin add premixed or basal insulin.  
Add alpha glucosidase inhibitor or DPP4 inhibitor or thiazolidinedione.  
Other option may be glucagon like peptide receptor agonist.
- D) Fourth line of therapy  
Begin with insulin therapy when lifestyle modification and oral antidiabetic medication could not control optimum blood glucose level.

### Insulin Therapy

Begin with basal insulin like Insulin detemir or Insulin glargine  
Or  
Once or twice daily premixed insulin  
Initiate insulin with a self-titration regimen (dose increases by 2 units by every 3 days) or with biweekly or more frequently by contacting with a healthcare professional.  
Premeal glucose target should be < 115 mg/dl.  
Explain that initial insulin level below but eventually insulin requirement may vary 30–100 units/day.  
Other oral antidiabetic medication may be continued.

### Comparative evaluation of recent guidelines on type 2 diabetes mellitus management

#### Comparison of screening guidelines

The WHO, ADA-EASD position statement, and IHS guidelines state that adult people should be screened for type 2 diabetes if their BMI >25 kg/m<sup>2</sup> and have one or more of the following risk factors: first degree relative with diabetes, women who delivered a baby weighing > 9 lb, diagnosis of polycystic ovarian syndrome, history of gestational diabetes mellitus (GDM), or acanthosis nigricans.<sup>20–22</sup> Although the basic guidelines remain the same, there are some differences in individual guidelines. The WHO recommends that adults having history of vascular disease to be screened every 3 years. The recommendation of ADA-EASD position statement also mentions that adults with age more than 45 years without any pre-existing conditions be screened every 3 years. The ADA-EASD position statement also recommends annual screening of pre-diabetic adults. However, the AACE guideline<sup>23</sup> has done away with the criterion of having a BMI >25 kg/m<sup>2</sup> in adults for diabetes screening. On the other hand, the AACE guideline has recommended that those adults having impaired glucose tolerance (IGT), or having a history of cardiovascular disease, physical inactivity, or are on antipsychotic therapy for schizophrenia or severe bipolar disorder; should only undergo screening tests for the presence of diabetes.<sup>23</sup> Another important screening criteria included in all the guidelines are the presence of HDL cholesterol <35 mg/dl or triglyceride level >250 mg/dl. Both the WHO and the ADA-EASD guidelines recommend that in the event of a normal screening test values, they should be repeated every 3 years.<sup>24</sup>

### Comparison of diagnosis guidelines

Almost all the guidelines are in unison as to the diagnostic criteria for type 2 diabetes mellitus. For non-pregnant adults, the diagnosis of diabetes mellitus is made if there is fasting plasma glucose (FPG) level  $\geq 126$  mg/dl or 2-h postprandial plasma glucose level of  $\geq 200$  mg/dl following a standard 75 mg oral glucose load.<sup>20,22,23</sup> In contrast, the WHO guideline also includes those with a random plasma glucose  $\geq 200$  mg/dl and having classic symptoms of hyperglycemia as a criteria for diagnosis.<sup>21</sup> In addition the AACE, ADA-EASD position statement, and IHS also recommend that a person having HbA1c > 6.5% can also be diagnosed as having diabetes.<sup>25</sup>

### Comparison of Guidelines for management

All the patients diagnosed with type 2 diabetes mellitus require elaborate and well-planned long-term management strategies. Diabetes self-management education and also medical nutrition therapy are considered the most effective early management strategies for type 2 diabetes. Proper education about the various facets of diabetes and self-management goes a long way towards helping the patients adhere to a long-term treatment process, achieving favorable glycemic control and weight reduction.<sup>24</sup> All the guidelines including the WHO, ADA-EASD, AACE are in agreement to recognize the importance of medical nutrition therapy and diabetes self-management education in management of type 2 diabetes.<sup>20–23,25</sup> Amongst all this, the ADA-EASD position statement guidelines recommend use of metformin as the first line drug in patients in whom it is not contraindicated due to some other reason.<sup>20</sup> However, the AACE guidelines recommend, instead of prioritizing a single medicine, a host of other drugs any of which may be started either alone or in combination depending on the initial HbA1c percentage.<sup>25</sup> Regarding HbA1c as a glycemic goal, the ADA-EASD position statement and the WHO guidelines have recommended an HbA1c < 7% in all type 2 diabetes patients.<sup>20,21</sup> However, in the recent 2016 guidelines of the ADA-EASD position statement, more stringent HbA1c goals like < 6.5% or even less stringent HbA1c goals such as < 8% may be considered based on individualized patient profile.<sup>20</sup> On the other hand, the AACE has recommended for an individualized goal of HbA1c as to < 6.5% for patients without severe illness and at low hypoglycemic risk, whereas for elder patients with concurrent serious illness and at risk for hypoglycemia, the goal may be even > 6.5%.<sup>23,25</sup> The ADA-EASD, AACE, and IHS also recommend HbA1c testing twice yearly or four times yearly for patients not at target.<sup>20,22,23,25</sup> Apart from glycemic management, there are also several subtle differences between different guidelines regarding management of other comorbidities that are frequently present in type 2 diabetic patients. The ADA-EASD position statement, WHO and AACE guidelines recommend initiation of aspirin (preferably in low dose) in diabetic patients having cardiovascular risk factors, more so in males having age > 50 years and females having age > 60 years.<sup>20–23,25</sup> With regard to lipid lowering therapy, the ADA-EASD, AACE, and IHS recommend initiation of statins

regardless of baseline levels unless contraindicated,<sup>20,22,23,25</sup> while the WHO guidelines only recommend starting statins if LDL-C level is high.<sup>21</sup> Daily foot care is given due importance in the ADA-EASD, AACE, and IHS guidelines except in WHO guidelines.<sup>20–22</sup> However, unlike the ADA-EASD position statement, the AACE guidelines do not lay any emphasis on annual comprehensive foot examinations.<sup>23,25</sup> Several micro- and macrovascular complications associated with diabetes markedly reduce the quality of life in patients. All the guidelines recommend yearly eye examination to be performed for screening retinopathy.<sup>20–23,25</sup> To identify and diagnose the diabetic nephropathy, another serious complication of long standing diabetic patients, annual testing of serum creatinine and urine albumin are recommended by all the guidelines.<sup>20–23,25</sup> The ADA-EASD and IHS guidelines also recommend screening for distal symmetric polyneuropathy at diagnosis and yearly thereafter.<sup>20,22</sup> Regarding alcohol intake in type 2 diabetics, only the ADA-EASD and IHS recommend to limit alcohol intake to a moderate amount ( $\leq 1$  drink/day for women and  $\leq 2$  drinks/day for men).<sup>20,22</sup> The ADA-EASD position statement also recommends assessing for few common diabetes-associated conditions like hearing impairment, obstructive sleep apnea, fatty liver disease, low testosterone in men, periodontal disease, cancers (liver, pancreas, endometrium, colon/rectum, breast, and bladder), fractures, cognitive impairment.<sup>20</sup> In contrast, the AACE only recommends screening for obstructive sleep apnea in men  $> 50$  years of age and regular assessment for diabetes associated depression.<sup>23,25</sup> Regarding management of hyperlipidemia, all the guidelines are generally in consensus that goals for lipids should be as follows: LDL-C  $< 100$  mg/dl in patients without overt CVD; LDL-C  $< 70$  mg/dl in patients with overt CVD; HDL-C  $> 40$  mg/dl in men, and  $> 50$  mg/dl in women; and a triglyceride level of  $< 150$  mg/dl.<sup>20–25</sup> Regarding medical management of prediabetes, the use of metformin therapy differs in the ADA and AACE guidelines. As per ADA-EASD position statement, metformin should be prescribed for patients with IGT, IFG, or and HbA1c of 5.7–6.4%; a BMI  $> 35$  kg/m<sup>2</sup>, age  $< 60$  years, or (for women) previous history of gestational diabetes mellitus.<sup>20,24</sup> Whereas as per the AACE guidelines, either metformin or a thiazolidinedione can be prescribed for younger patients who are at moderate to high risk for developing diabetes; patients with additional risk factors like hypertension, dyslipidemia, or polycystic ovarian syndrome; patients with a family history of diabetes in a first degree relative, and in obese persons. The ADA-EASD and IHS guidelines also recommend annual influenza vaccine for diabetic patients.<sup>20,22</sup>

## CONCLUSION

The present review of the various popular guidelines for the management of type 2 diabetes mellitus summarizes the basic aspects of screening, diagnosis, management, and treatment of associated comorbid diseases. All the guidelines are quite well accepted in various parts of the world, however from a physician's point of view it is very important to note the areas where there are certain disagreements among these guidelines. Although management of type 2 diabetes mellitus requires individualized patient-centric approach, yet

it is of utmost importance to keep in mind the basics of the guidelines and follow a holistic approach towards achieving successful treatment outcome.

## REFERENCES

1. International Diabetes Federation. International Diabetes Federation [Internet]; 2015 [cited 14 October 2015]. Available from: <http://www.idf.org>.
2. Endocrine practice, 21:4:2015, DOI: 10.4158/EP15693, CS; 2015.
3. DAFNE Study Group. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: Dose Adjustment For Normal Eating (DAFNE) randomised controlled trial. *BMJ* 2002;325:746.
4. Kulkarni K, Castle G, Gregory R, Holmes A, Leontos C, Powers M, et al. The Diabetes Care and Education Dietetic Practice Group. Nutrition practice guidelines for type 1 diabetes mellitus positively affect dietitian practices and patient outcomes. *J Am Diet Assoc* 1998;98:62–70; quiz 71–72.
5. Rossi MCE, Nicolucci A, Di Bartolo P, Bruttomesso D, Girelli A, Ampudia FJ, et al. Diabetes Interactive Diary: a new telemedicine system enabling flexible diet and insulin therapy while improving quality of life: an open label, international, multicentre, randomized study. *Diabetes Care* 2010;33:109–115.
6. Laurenzi A, Bolla AM, Panigoni G, Doria V, Uccellatore A, Peretti E, et al. Effects of carbohydrate counting on glucose control and quality of life over 24 weeks in adult patients with type 1 diabetes on continuous subcutaneous insulin infusion: a randomized, prospective clinical trial (GIOCAR). *Diabetes Care* 2011;34:823–827.
7. Scavone G, Manto A, Pitocco D, Gagliardi L, Caputo S, Mancini L, et al. Effect of carbohydrate counting and medical nutrition therapy on glycaemic control in type 1 diabetic subjects: a pilot study. *Diabetes Med* 2010;27:477–479.
8. UK Prospective Diabetes Study (UKPDS) Group. Effective of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet* 1998;352:854–865.
9. Rickheim PL, Weaver TW, Flader JL, Kendall DM. Assessment of group versus individual diabetes education: a randomized study. *Diabetes Care* 2002;25:269–274.
10. Zeimer DC, Berkowitz KJ, Panayiotou RM, El-Kebbi IM, Musey VC, Anderson LA, et al. A simple meal plan emphasizing healthy food choices is as effective as an exchange based meal plan for urban African Americans with type 2 diabetes. *Diabetes Care* 2003;26:1719–1724.
11. Wolf AM, Conaway MR, Crowther JQ, Hazen KY, Nadler J, Oneida B, et al. Improving Control with Activity and Nutrition (ICAN) Study. Translating lifestyle intervention to practice in obese patients with type 2 diabetes: Improving Control with Activity and Nutrition (ICAN) study. *Diabetes Care* 2004;27(7):1570–1576.
12. Nield L, Moore HJ, Hooper L, Cruickshank JK, Vyas A, Whittaker V, et al. Dietary advice for treatment of type 2 diabetes mellitus in adults. *Cochrane Database Syst Rev* 2007;3:CD004097.
13. Davis RM, Hitch AD, Salaam MM, Herman WH, Zimmer-Galler IE, Mayer-Davis EJ. Tele health improves diabetes self-management in an underserved community: diabetes telecare. *Diabetes Care* 2010;33:1712–1717.
14. Coppel KJ, Kataoka M, Williams SM, Chisholm AW, Vorgers SM, Mann JI. Nutritional intervention in patients with type 2 diabetes who are hyperglycaemic despite optimised drug treatment – Lifestyle Over and Above Drugs in Diabetes (LOADD) study: randomized controlled trial. *BMJ* 2010;341:c3337.
15. Franz MJ, Monk A, Barry B, McClain K, Weaver T, Cooper N, et al. Effectiveness of medical nutrition therapy provided by dietitians in the management of non-insulin-dependent diabetes mellitus: a randomized controlled clinical trial. *J Am Diet Assoc* 1995;95:1009–1017.
16. Evert AB, Boucher JL, Cypress M, Dunbar SA, Franz MJ, Mayer-Davis EJ, et al. Nutrition therapy recommendations for the management of adults with diabetes. *Diabetes Care* 2014;37 (Suppl. 1):S120–S143.
17. DAFNE Study Group. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: Dose Adjustment For Normal Eating (DAFNE) randomised controlled trial. *BMJ* 2002;325:746.
18. Kulkarni K, Castle G, Gregory R, Holmes A, Leontos C, Powers M, et al. The Diabetes Care and Education Dietetic Practice Group. Nutrition practice

- guidelines for type 1 diabetes mellitus positively affect dietician practices and patient outcomes. *J Am Diet Assoc* 1998;98:62–70; quiz 71–72.
19. Courcoulas AP, Goodpaster BH, Eagleton JK, Belle SH, Kalarchian MA, Lang W, et al. Surgical vs medical treatment for type 2 diabetes mellitus: a randomized clinical trial. *JAMA Surg* 2014;149:707–715.
  20. American Diabetes Association: Standards of medical care in diabetes—2016. *Diabetes Care* 2016;39(Suppl. 1):S6–S104.
  21. Khatib O. Guidelines for the Prevention, Management and Care of Diabetes Mellitus. World Health Organization: Brussels, Belgium, 2006.
  22. Indian Health Service. Standard of care and clinical practice recommendations: type 2 diabetes, 2011.
  23. Handelsman Y, Mechanick J, Blonde L, Grunberger G, Bloomsgarden Z, Bray G, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan. *Endocr Pract* 2011;17:1–53.
  24. Tan E, Polello J, Woodard L. An evaluation of the Current Type 2 Diabetes Guidelines: where they converge and diverge. *Clin Diabetes* 2014;32(3):133–139.
  25. Garber A, Abrahamson M, Barzilay J, Blonde L, Bloomsgarden Z, Bush M, et al. AACE/ACE comprehensive diabetes management algorithm 2015. *Endocrine Pract* 2015;21(4):438–447.

**How to cite this article:** Das S, Das A. A comparative review of the current management guidelines in type 2 diabetes mellitus. *IntJMRP* 2016;1(2):pp–pp.

**Source of Support:** None declare. **Conflict of Interest:** None.

## Oral anti-diabetics: What after metformin

Submission: 00-00-2016

Revision: 00-00-2016

Publication: 00-00-2016

### INTRODUCTION

Diabetes has become a global burden now and India has unfortunately secured the second position in the world. For years we have gone through the same debate about the medication in type 2 diabetics after failing of lifestyle intervention. Metformin has become the gold standard to start with but we are in a dilemma what to start after that. In the past 15 years there have been tons of new drug inventions in the field of diabetes. Individualization of drugs has been stressed for many years. It has been seen that too tight control in moribund patients with increased age might in fact be detrimental and those with newly diagnosed diabetes of young age, tight glycemic control gives a good glycemic memory, and finally less microvascular complications. Hence the patient group selection is very important.

There are advantages and disadvantages of every group of drug. On the basis of these and balancing the advantages and disadvantages, one has to take decision about the selection of right drug for the right patient at right time with right dose, at right route and at right interval. Sulfonylureas (SUs) are cheap, easily available, and have good initial efficacy. But chance of hypoglycemia is a major drawback of these drugs. Weight gain, poor long-term efficacy are other drawbacks. Some studies have highlighted that SUs have relation with increased destruction of beta cells. Even cardiac safety of these drugs has been questioned (although most studies have been carried out with glibenclamide).

Thiazolidinediones have certain advantages like low risk of hypoglycemia and are cheap. Another very important advantage is that it targets insulin resistance. But again these drugs cause weight gain. Heart failure is another complication. Increased risk of bone fracture often restricts the use of these drugs in elderly population, particularly female. Some studies have highlighted its relationship with bladder cancer, though it is still debatable.

Dipeptidyl peptidase 4 inhibitors (DPP4 inhibitors) are unique group of drugs which does not have potentiality for hypoglycemia. There is no effect on body weight. In hypoglycemia it promotes increased glucagon response. Its efficacy is sustained. From US FDA good cardiovascular safety data is available. However increased risk of hospitalization due to heart failure by saxagliptin is quite particular as the savor group selected very high risk individuals with some already having increased pro-BNP levels but the hazard ratio is seen to be coming down after the initial phase. DPP4 inhibitors decrease inflammatory markers and decreased carotid intima thickness (spike trial of Sitagliptin). Dedicated study shows that some gliptins have favorable results in

nephropathy and can be used in all eGFR. These are safe in elderly. Main disadvantage of gliptins are that they are costly (except the US-FDA and European body non-recognized molecules). They cannot be used in patients having history of pancreatitis.

SGLT2 inhibitors are another new group of drugs. They work by novel mechanism of action sparing pancreas. They also have no risk of hypoglycemia. Four years efficacy data of these drugs are satisfactory. They promote weight loss. They have excellent cardiovascular safety data (in fact superiority data available). They address insulin resistance by promoting visceral fat loss. They promote increased uric acid excretion though its significance yet to be known. It has nephro-protective theoretical hypothesis. In spite of all these advantages there are certain disadvantages: they are costly. As they promote increased fluid loss, so they are to be avoided in aged and in very young patients. They should be used very cautiously with loop diuretics. There is increased chance of genitor urinary infections; though recurrence rate is low. There is increased chance of euglycemic diabetic ketoacidosis (DKA) if wrong group of patient is selected. Another restriction of these drugs is that long-term safety data is yet to be available. There is increased risk of bone fracture and increased chance of potassium imbalance with canagliflozin. These drugs cannot be used in low eGFR (particularly if it is less than 45 ml/min).

### CONCLUSION

Based on the available data the clinicians have to choose an agent depending on the economic status, profession, age and existing co-morbidities of an individual. Every patient is unique and hence the same glycemic targets should not be set for all. Diabetes management is changing each day. Newer drugs addressing the underlying pathologies and acting in a novel mechanism are always welcome.

**Sayak Roy**

*Sayak Roy, MBBS, MRCPGP Diploma in diabetes*

### Address for Correspondence:

Sayak Roy,  
MBBS, MRCPGP Diploma in diabetes

**How to cite this article:** Roy S. Oral anti-diabetics: What after metformin. IntJMRP 2016;1(2):pp-pp.

**Source of Support:** None declare. **Conflict of Interest:** None.



## Bilateral linguofacial trunk in a cadaver

Arpan Haldar

Department of Anatomy, ESI-PGIMSR, Joka, Kolkata

Submission: 12-07-2016

Revision: 30-08-2016

Publication: 30-09-2016

### INTRODUCTION

External carotid artery (ECA) irrigates large areas of head and neck being a vascular element of a great importance in surgical and radiological procedures.<sup>1,2</sup> It is known that ECA presents variations in the distribution in its anterior branches<sup>3,4</sup> finding common origins in forming trunks which can be thyro-linguo-facial truncus, thyro-lingual truncus, and linguo-facial trunks.<sup>5</sup> The linguo-facial trunk (LFT) has shown between 6% and 20% in analyzed cases and generally it is the most common of variations<sup>6,7</sup> not showing preference for one side or other.<sup>1</sup> These anatomical variations remain unnoticed during the life of an individual, but they become more important when there are changes associated with aging such as loss of elasticity of the trunk or aneurysms development of the trunk which are pathogenic.<sup>8</sup>

### MATERIALS AND METHODS

During routine dissection of head and neck for undergraduate students, in a 70-year-old male cadaver in the Department of Anatomy, ESI Post Graduate Institute of Medical Sciences and Research, Joka, Kolkata, the bifurcation of the common carotid artery (CCA) was exposed as were the branches of the ECA. The dissection in the neck was performed according to the conventional technique, carefully pulling the skin, the deep cervical fascia, sternocleidomastoid muscle and separating the internal jugular vein (IJV) and vagus nerve on both sides of body. Branching pattern of the ECA were examined on both sides and variations were found which were dissected carefully and photographed (Fig. 1).

### OBSERVATIONS

The branching of the CCA of both sides was normal but LFT were observed over the beginning of the superior thyroid artery on both sides. On both sides distal to carotid bifurcation the ECA and its anterior branches was located lateral to ICA and medial to IJV. ECA gave rise to the superior thyroid artery 1 cm above the bifurcation below the tip of greater cornu of hyoid bone and LFT 3 cm from the bifurcation at the level of laryngeal prominence. The LFT measured was 5 cm of length in right side and 6 cm on left side from the beginning in ECA, until its bifurcation in facial artery and lingual artery. LFT first ran forwards and medially and then divides into lingual and facial arteries, medial to internal carotid artery (ICA). The lingual artery ascended vertically



Figure 1: Linguofacial trunks in cadaver

up, crossed the IJV, laryngeal nerve taking an oblique course it passed underneath the hypoglossal nerve and anterior belly of digastric muscle to enter digastric triangle. The occipital artery arose from the posterior part of ECA opposite the origin of linguofacial trunk and coursed upwards and backwards. The ascending pharyngeal artery took origin from the medial side of ECA slightly distal to the origin of LFT from ECA travelling between it and ICA. Posterior auricular artery arose above the level of occipital artery from ECA (Figs. 2 and 3).

### DISCUSSION

Variations in branching pattern in ECA were observed which more or less correlated with earlier study, but the LFT length was 7.3 cm and 9.4 cm in origin and artery bifurcation of CCA.<sup>6</sup> Anatomical studies have revealed the presence of LFT unilaterally in 20% of population.<sup>1</sup> According to a study done by Berman *et al.*<sup>9</sup> facial artery may replace lingual artery and supply the sublingual gland. Linguofacial trunk bilaterally in 4.8%<sup>1</sup> population and 28.6% population have also been reported.<sup>10</sup> The facial artery passed upwards and forwards and reached posterior part of submandibular gland. Mata *et al.*<sup>11</sup> report a LFT frequency in 19.9% case of dissections and at the same time Troupis *et al.*<sup>6</sup> only two cases (6%). Fazan *et al.*<sup>1</sup> present it most frequently 20% in the right side and 24% in left side, only two corpses (4.9%) show a bilateral LFT information that represents low level of LFT in both sides of





Figure 2: Linguofacial trunk on left side



Figure 3: Linguofacial trunk on right side

neck. Ahmad *et al.*<sup>12</sup> described that lingual and facial arteries originating from LFT had thicker in its wall and higher density of elastic fibres, which is associated according to Li *et al.*<sup>13</sup> to present chances developing pseudoaneurysms in ECA after catheterization procedures. According to Anil<sup>14</sup> the lingual artery arises from a common trunk with the facial as a linguofacial trunk in 10–20% of cases. Knowledge of variations in ECA branches is very important for surgical, radiological, and diagnostic procedures and interventions in the head and neck.<sup>3</sup>

## CONCLUSION

Knowledge of variations of ECA and its branches and their recognition during diagnostic imaging are also important for vascular surgical procedures in the region, such as carotid endoplasty for treatment of carotid stenosis<sup>15,16</sup> or extracranial intracranial arterial bypass for treatment of patients with occlusive cerebrovascular diseases, skull-base tumors or aneurysms.<sup>17</sup> Knowledge is also essential for understanding and interpretation of diagnostic angiograms as well as performing surgical procedures and vascular surgeons to prevent diagnostic errors, influence tactics and interventional procedures and avoid complications during surgery in the cervical region. Since these variations are asymptomatic, the detection will depend on imaging tests<sup>6</sup> for characterize the vascular anatomy and reduce the chances of collateral injury.

## EMBRYOLOGICAL EXPLANATION

The development of the ECA and its branches (Fig. 4) is incompletely understood.<sup>18</sup> The variations might be related to changes in the transformation of the aortic arch system in the embryo.<sup>19</sup> The ECA is formed after a complicated process of angiogenesis.<sup>20</sup> It includes annexation and regression of the vessels with some remodeling. The development begins through a combination of outgrowths from some vessels, involution of others and assimilation of pre-existing channels that arise from undifferentiated precursor vessels.<sup>18</sup> The carotid bifurcation area and the CCA derive from the third aortic arch, while the ECA derives from the first arch with some contribution from the second aortic arch.<sup>21</sup> According to Larsen,<sup>21</sup> the trunks of the ECA arise as outgrowths from the third aortic arches. Various ventral vestiges of the first and second aortic arch arteries and ventral aorta form the ventral pharyngeal artery which later becomes the main stem of the ECA. The ventral pharyngeal artery undergoes further modifications and gives the identity of the ECA and its branches. Deviation in the normal stages of annexation and regression during angiogenesis leads to the anomalous structures (Fig. 5).<sup>20</sup>




Figure 4: ECA and its branches




Figure 5: Different types of anomalous branching pattern of ECA

## REFERENCES

- Fazan VP, da Silva JH, Borges CT, Ribeiro RA, Caetano AG, Filho OA. An anatomical study on the linguo-facial trunk. *Surg Radiol Anat* 2009; 31(4):267–270.
- Hayashi N, Hori E, Ohtani Y, Ohtani O, Kuwayama N, Endo S. Surgical anatomy of the cervical carotid artery for carotid endarterectomy. *Neurol Med Chir (Tokyo)* 2005;45(1):25–29.
- Iwai T, Izumi T, Inoue T, Maegawa J, Fuwa N, Mitsudo K, et al. Thyrolinguofacial trunk arising from the common carotid artery identified by three-dimensional computed tomography angiography. *Surg Radiol Anat* 2012;34(1):85–88.
- Nirmaladevi M, Sruthi G. Linguo-facial trunk – a case report. *Anat Karnataka* 2010;4(2):54–56.
- Lucev N, Bobinac D, Maric I, Drescik I. Variations of the great arteries in the carotid triangle. *Otolaryngol Head Neck Surg* 2000;122(4):590–591.
- Troupis TG, Dimitroulis D, Paraschos A, Michalinos A, Protogerou V, Vlasis K, et al. Lingual and facial arteries arising from the external carotid artery in a common trunk. *Am Surg* 2011;77(2):151–154.
- Jadhav SD, Ambali MP, Patil RJ. Anatomical variation of the origin of the right lingual artery. *Int J Anat Var* 2011;4:75–76.
- Zumre O, Salbacak A, Cicekcibasi AE, Tuncer I, Seker M. Investigation of the bifurcation level of the common carotid artery and variations of the branches of the external carotid artery in human fetuses. *Am Anat* 2005;187(4):361–369.
- Bergman RA, Afifi AK, Miyauchi R. *Illustrated Encyclopedia of Human Anatomic Variation: Opus II Cardiovascular system: Arteries, Head, Neck and Thorax. Common Carotid Arteries*, 2013.
- Yonenaga K, Tohnai I, Mitsudo K, Mori Y, Saijo H, Iwai T, et al. Anatomical study of the external carotid artery and its branches for administration of superselective intra-arterial chemotherapy via the superficial temporal artery. *Int J Clin Oncol* 2011;16(6): 654–659.
- Mata JR, Mata FR, Souza MC, Nishijo H, Ferreira TA. Arrangement and prevalence of branches in the external carotid artery in humans. *Ital J Anat Embryol* 2012;117(2):65–74.
- Ahmad R, Al-Shaarawy S, Attaya M, Al-Fayez M, Aldahmash A, Mohal S, et al. Anatomical variations of lingual and facial arteries in male cadavers and histological study of their structure. *Int J Integr Biol* 2012;13(1):36–39.
- Li SH, Hsu SW, Wang SL, Chen HC, Huang CH. Pseudoaneurysm of the external carotid artery branch following radiotherapy for nasopharyngeal carcinoma. *Jpn J Clin Oncol* 2007;37(4):310–313.
- Anil A, Turgut Hb, Peker T, Pelin C. Variations of the branches of the external carotid artery. *Gazi Med J* 2000;11(2):81–83.
- Brown MM, Butler P, Gibbs J, Swash M, Waterston J. Feasibility of percutaneous transluminal angioplasty for carotid artery stenosis. *J Neurol Neurosurg Psychiatr* 1990;53:238–243.
- Dhillon EH, Van Leeuwen MS, Fernandez MA, Eikelboom BC, Mali WPTM. CT Angiography application to the evaluation of carotid artery stenosis. *Radiology* 1993;189:211–219.
- Gratzl O, Schmiedek P, Spetzler R, Steinhoff H, Marguth F. Clinical experience with extra-intracranial arterial anastomosis in 65 cases. *J Neurosurg* 1976;44:313–324.
- Osborn AG, Jacobs JM. External carotid artery. In: Osborn AG, Ed. *Diagnostic Cerebral Angiography*. 2nd ed. Philadelphia: Lippincott Williams and Wilkins, 1999: 31–56.
- Eid N, Ito Y, Otsuki Y. Anomalous branching pattern of external carotid artery: clinical relevance to cervicofacial surgery. *Clin Anat* 2011;24:953–955.
- Mahendrakar MA. Variation in the branching pattern of external carotid artery: a case report. *J Anat Soc India* 2007;56:47–51.
- Larsen WJ. Development of the vasculature. In: *Human Embryology*. 2nd ed. New York: Churchill Livingstone, 1997: 191–195.

## Address for Correspondence:

Dr. Arpan Haldar,  
Department of Anatomy, ESI-PGIMS, Joka, Kolkata.

**How to cite this article:** Haldar A. Bilateral linguofacial trunk in a cadaver. *IntJMRP* 2016;1:pp–pp

**Source of Support:** None declare. **Conflict of Interest:** None.